A Closer Look: Colorectal Cancer National Coverage Decision After One Year
Executive Summary
Nearly a year after CMS finalized a contentious national coverage decision (NCD) on certain off-label uses of colorectal cancer drugs, five out of nine eligible clinical trials have yet to open for patient enrollment, according to the National Cancer Institute (NCI)
You may also be interested in...
Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes
Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.
ESA Stakeholders May Find Clues About Medicare Revisions In Device NCDs
Pharma stakeholders could face an uphill battle convincing CMS to revise its recent final Medicare national coverage determination for the use of erythropoiesis-stimulating agents for non-renal indications, unless they can cite newly available published data, CMS' history of NCD reconsiderations suggests
ESA Stakeholders May Find Clues About Medicare Revisions In Device NCDs
Pharma stakeholders could face an uphill battle convincing CMS to revise its recent final Medicare national coverage determination for the use of erythropoiesis-stimulating agents for non-renal indications, unless they can cite newly available published data, CMS' history of NCD reconsiderations suggests